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Preterm infants are at high risk for developing “respiratory distress
syndrome” (RDS) as a result of insufﬁcient surfactant production [1,2].
The delayed onset of fetal surfactant synthesis [3] and the resulting
increased risk for the development of RDS [4] in the male fetus are
well known. Higher intrauterine androgen levels and interactions
with transforming growth factor β receptor signaling pathways have
been implicated in the mechanism of the sex-speciﬁc delay in lung
maturation [5]. Female sex is associated with a lower incidence of RDS
in premature infants [6]. The fetus is exposed to increased levels of
estrogen and progesterone [7]. Despite this fact, replacement of these
placental hormones does not decrease the incidence of bronchopul-
monary dysplasia [8], the long-term pulmonary morbidity of preterminfants born with immature lungs. Estrogens are steroid hormones
and there are two subtypes of estrogen receptors (ERs), ERα and ERβ.
They belong to a large superfamily of nuclear receptors and act as
ligand-activated transcription factors [9]. The development of
multiple mammalian organ systems, including the reproductive
system, skeletal, muscle, and brain, are dependent on estrogen
[10,11]. ERβ is highly expressed in fetal pneumocytes (types I
and II) [12] and deletion of fetal ERβ leads to fewer alveoli and
reduced elastic recoil in adult mice [13]. This phenotypical picture is
similar to the alveolar simpliﬁcation and hyperreactive airway system
seen in ErbB4-deleted lungs [14]. ErbB4 is the signaling receptor for
the growth factor neuregulin (NRG). NRG is secreted by mature fetal
lung ﬁbroblasts and plays an important role in the initiation of fetal
surfactant synthesis in type II epithelial cells [15]. It acts in a paracrine
manner through mesenchymal–epithelial cell communication and
signals its effects through formation of ErbB receptor dimer. ErbB4 is
the preferred dimerization partner and functions as a ligand-induced
co-factor for other transcription factors in fetal type II cells [16]. ErbB4
receptor is known for its involvement in differentiation processes
[17–20] and is unique among transmembrane tyrosine kinase
receptors. Its intracellular domain (4ICD) is proteolytic cleaved by
TNFα-converting enzyme and translocated to the nucleus after being
released into the cytosol [21] and processed by presenilin-dependent
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site [24] and an intrinsic nuclear localization sequence (NLS), which
enables it to be translocated to the nucleus to activate gene expression
leading to proliferation, cell cycle arrest, apoptosis, or differentiation.
Shuttling of 4ICD between different subcellular compartments may
regulate multiple cell functions including life or death decisions in a
cell [18]. Since ErbB receptors interact with transcription factors [25]
and nuclear receptors [26] and lung phenotypes of deletion of ERβ and
ErbB4 are similar, we hypothesized that at least parts of the estrogen
effects on lung development are signaled through interaction with
ErbB4 signaling pathways. More detailed knowledge of the regulation
of signaling pathways involved in lung development will help to
create additional treatment options via enhancement of their biologic
effects.
2. Materials and methods
2.1. Materials
Rabbit polyclonal ERβ (H-150), rabbit polyclonal IgG ErbB4 (C-18),
and normal rabbit IgG were obtained from Santa Cruz Biotechnology
(Heidelberg, Germany); mouse monoclonal c-ErbB4 antibody (clone
HFR-1) was from Thermo Fisher scientiﬁc GmbH (Dreieich, Germa-
ny); goat anti-rabbit IgG (HRP-labeled, H+L), goat anti-mouse IgG
(HRP-labeled, H+L) and rabbit anti-mouse IgG (H+L) were from
Zymed Laboratories Inc (South San Francisco, CA); rabbit anti-sheep
Sftpb was from Chemicon Europe (Schwalbach/Ts, Germany);
puriﬁed mouse anti-phosphotyrosine antibody was from BD Bio-
sciences (Heidelberg, Germany); mouse monoclonal anti-actin clone
AC-40, 4,6-Diamidino-2-phenylindole, dilactate (DAPI) and 17-β-
estradiol were obtained from Sigma (Hamburg, Germany); Alexa
Fluor 488 goat anti-mouse IgG (H+L) and Alexa Fluor 568 anti-rabbit
IgG (H+L) were from Molecular Probes (Karlsruhe, Germany).
The Nanofectin™ transfection reagent was obtained from PAA-
Laboratories (Pasching, A) and cDNA Kit was from Amersham
Biotechnologies (Munich, Germany). Total RNA Isolation Reagent
(TRIR) was obtained from ABgene (Darmstadt, Germany) and Plasmid
Midi Kit from Qiagen (Hilden, Germany). The Dual-Glo Luciferase
assay System was from Promega (Mannheim, Germany). TaqMan
Universal PCR Master Mix and ABI PRISM™ Big Dye Terminator Cycle
Sequencing Ready Reaction Kit were from Applied Biosystems
(Darmstadt, Germany). ChIP Assay Kit was from USB Corporation
(Staufen, Germany). The forward primers (FP), reverse primers (RP)
and probes for Actb, Sftpb[14] and the Sftpb promoter were from
Eurogentec (Cologne, Germany). Neuregulin 1β producer cells were
kindly provided by Dr. Kermit Carraway III. (UC Davis, CA), and the
growth factor was puriﬁed by the Phoenix Laboratory, Ann Kane
(Tufts University, Boston, MA).
2.2. Cells
The mouse lung epithelial cell line (MLE-12) was obtained from
American Type Culture Collection (Wesel, Germany). This line was
established from pulmonary tumors in a mouse transgenic for the
SV40 large T antigen under the control of the promoter region of the
human surfactant protein C gene. The cells secrete phospholipids in
response to phorbol esters and ATP, but not in response to Forskolin
[27]. We used the MLE-12 cell line for all experiments since they
express ErbB4, ERβ, and Sftpb similarly to primary fetal type II cells.
Using primary cells would have required many time-dated pregnant
animals since primary cells are less efﬁciently transfectable. MLE-12
cells, on the other hand, are easily transfectable and are known for
maintaining functional characteristics of distal respiratory epithelial
cells, including the expression of surfactant proteins and mRNAs and
the ability to secrete phospholipids [27].2.3. Plasmids
pEGFP N3 (control), pHER4 (full length ErbB4 receptor), pHER4-
MuNLS (abrogated nuclear localization sequence), and pHER4V673IMu
(abolished γ-secretase processing domain)were kindly provided by Dr.
Frank Jones (Tulane University, New Orleans) [25]. YFPERβ was kindly
providedbyDr. ElenaKorenbaum(HannoverMedical School, Germany)
[28]. Sftpb promoter luciferase reporter plasmidwas kindly provided by
Philip L. Ballard (University of California, San Francisco, CA) [29].
2.4. MTT-Assay
Cell number was examined using an MTT-assay. In this colorimet-
ric assay, the yellow MTT is reduced to purple formazan in the
mitochondria of living, metabolically active cells. The amount of
formazan is directly proportional to the cell number [30]. MLE-12 cells
were plated and grown to 50% conﬂuence in a 96-well plate at a
concentration of 2.5×10³ cells per well. After a 3-hour serum
starvation, cells were treated for 24 h with serum-free DMEM
(controls), 17-β-estradiol (50, 100, 500, 1000, and 1500 pmol/l), or
NRG (5 nM, 10 nM 20 nM, 33 nM, 40 nM and 100 nM). Different
treatment concentrations were equally mixed from a stock solution to
keep the vehicle media content similar. After incubating with MTT-
solution for 2 h at 37 °C, the reactionwas stopped by Isopropanol–HCl.
Medium was removed and 3% SDS and Isopropanol–HCl was added.
Absorption was measured at 570 nm.
2.5. RNA isolation and cDNA synthesis
Cells were plated on culture dishes until they reached 90%
conﬂuence. After being serum starved for 3 h, cells were treated
with serum-free DMEM (controls), 17-β-estradiol (1000 pmol/l), or
NRG (33 nM) for 24 h. Total RNA Isolation Reagent (TRIR) was used
for cell lysis. RNA was isolated by guanidinium thiocyanate lysis
followed by acid phenol/chloroform extraction [31]. After reversed
transcription, 5 μg of total RNA was used in a 15 μl reaction volume
containing 1× DTT, 0.2 μg Hexamer Primer and 5× Bulk Mix for 1 h.
The resulting cDNA was used for real-time ampliﬁcation reactions.
2.6. Real time polymerase chain reaction (RT-PCR)
The cDNA levels of the Sftpb gene and of the Actb gene were
measured by real-time PCR. Actin was used as internal control to
normalize the surfactant protein cDNA levels. We used actin as a
housekeeping gene since stimulation with 17-β-estradiol (24.8±0.5,
n=6, p=0.4), NRG (24.7±0.4, n=6, p=0.3), or overexpression
with ERβ (23.7±0.1, n=5, p=0.2) did not change the Actb mRNA
expression when compared to control cells (25.5±0.5, n=7) or
EGFP-transfected cells (23.4±0.2, n=5), respectively (data not
shown). The 20 μl reaction mixture contained 1 μl of the cDNA
template, 10 μl TaqMan universal master mix, 300 nm each of forward
primer (FP) and reverse primer (RP), and 200 nm probe [14]. For
ampliﬁcation and detection of speciﬁc products the ABI PRISM 7900
sequence detection system was used. The ampliﬁcation protocol
consists of an initial denaturation and enzyme activation at 95 °C for
10 min, followed by 45 cycles at 95 °C for 15 s, and 60 °C for 1 min.
The threshold cycle [32] was determined for each gene. Samples were
run in quadruplicates. A semiquantitative method was used to
estimate the relative expression level of the surfactant protein
genes, which was done by calculating the DCt value, (difference in
the Ct values of the target and the reference gene). The Ct (cycle
threshold) is deﬁned as the number of cycles required for the
ﬂuorescent signal to cross the threshold. The difference in the Ct
values of the treated cells compared to the control cells was presented
as –DDCt (DDCt values are inversely proportional to the levels of
surfactant protein mRNA). For each assay, speciﬁcity was conﬁrmed
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electrophoresis with POP-6™-Polymer on an ABI 3100 Genetic
Analyzer (Applied Biosystems).
2.7. Co-immunoprecipitation and Western blotting
MLE-12 cells were plated in culture dishes until 90% conﬂuence.
Cells were serum starved for 24 h and stimulated with serum-free
DMEM (controls), 17-β-estradiol (1000 pmol/l), or NRG (33 nM) for
2 min and lysed in co-immunoprecipitation buffer (20 mM Tris (pH
7.4), 150 mM NaCl, 1 mMMgCl2, 1% TritonX-100, 10% Glycerol, 1 mM
Na3VO4, 1 mM NaF, 1 mM ZnCl2, 10 mM β-glycerol phosphate, 5 mM
tetrasodium pyrophoshate, 1 mM phenylmethylsulfonylﬂuoride
(PMSF) and 4 mg/ml each of aprotinin, leupeptin and pepstatin).
Lysates were cleared by microcentrifugation at 4 °C for 15 min. A
protein assay was used to determine total concentration of protein.
300 μg of total protein was incubated for 90 min with the speciﬁc
receptor antibody (anti ErbB4 C-7, anti ERβ H-150) at 4 °C. Protein-A-
sepharose was added and incubation was continued at 4 °C for
another 90 min. The beads were collected by microcentrifugation at
14,000 rpm for 10 min, washed with co-immunoprecipitation wash-
ing buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1%
TritonX-100, 1 mM Na3VO4, 1 mM NaF, 1 mM ZnCl2, 10 mM β-
glycerol phosphate, 5 mM tetrasodium pyrophoshate, 1 mM PMSF
and 4 mg/ml each of aprotinin, leupeptin and pepstatin), and boiled in
Laemmli buffer for 5 min at 100 °C. The proteins were separated
by 10% SDS-polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane. Blots were blocked in 1% BSA and incubated
with antibodies against individual proteins (puriﬁed mouse anti-
phosphotyrosine antibody, anti-ERβ H-150, anti-ErbB4 C-18, anti-
Sftpb, or anti-actin) overnight at 4 °C. Secondary antibody (goat anti-
mouse IgG or goat anti-rabbit IgG, both HRP-labeled) was applied and
the proteins were visualized by enhanced chemiluminescence [33].
Membranes were stripped in strip buffer (62.5 mM Tris (pH 6.8), 2%
SDS, 0.8% β-mercaptoethanol) for 30 min at 50 °C up to three times.
We performed an immunoprecipitationwith a control IgG antibody to
control for the antibody speciﬁcity.
2.8. Confocal microscopy
MLE-12 cells were grown on glass cover slips in 24-well plates for
24 h. After a serum starvation of 3 h, cells were treated with serum-
free DMEM (controls) or stimulated for 2 min, 30 min, 1 h, 4 h, 8 h,
12 h, or 24 h with either 17-β-estradiol (1000 pmol/l) or NRG
(33 nM). Cells were washed with PBS, ﬁxed for 20 min in 3%
paraformaldehyde, rinsed again with PBS, permeabilized in 0.5%
TritonX-100/ PBS for 5 min and blocked for 1 h with 10% normal goat
serum. After incubating with primary antibody (ErbB4 clone HFR-1,
ERβ H-150) for 30 min, cells were washed with PBS and incubated
with secondary antibody (Alexa Fluor 488, Alexa Fluor 568) for
another 30 min. After staining with DAPI for 10 min, cells were
mounted onto glass slides and examined using a Leica Inverted-2 DM
IRB confocal laser scanning microscope connected to a TCS SP2 AOBS
scanhead (Leica, Wetzlar, Germany).
2.9. Transfection experiments
To examine the effects of overexpression of ERβ and to study Sftpb
promoter activation, MLE-12 cells were transfected with an ERβ
construct (YFPERβ) [28], an ErbB4 construct (pHER4), or an empty
control construct (pEGFP N3) [25]. The cells were transfected for 48 h
using Nanofectin transfection reagent as described by the manufac-
turer. Brieﬂy, cells were grown to 50% conﬂuence in 96-well plates
(for MTT assay and luciferase assay) or on 6-well plates (for real time
PCR). 0.25 μg DNA (96-well plates) or 3 μg DNA (6-well plates) was
diluted with the Nanofectin solution and incubated for 30 min beforeit was added drop-wise into the serum containing medium. To study
the effect of estrogen on the ErbB4 nuclear translocation, cells were
grown on glass cover slips and transfected with pHER4 (full-length
ErbB4 receptor), pHER4MuNLS (defective nuclear localization se-
quence), or pHER4V673IMu (abolished γ-secreatase processing
domain) as described above.
2.10. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was done using a ChIP
assay kit as described by the manufacturer. Brieﬂy, MLE-12 cells
were cultured until conﬂuence in culture dishes. Cells were serum
starved for 3 h and treated with DMEM (control), 17-β-estradiol
(1000 pmol/l), or NRG (33 nM) for 24 h. Cells were cross-linked with
1% formaldehyde and chromatin was sonicated to an average size of
200 to 1000 bp. For immunoprecipitation the sonicated chromatin
was incubated over night with 5 μg antibody (ErbB4 C-18 or ERβ H-
150). The input DNA was used as a positive control (Input) and a no
antibody containing negative control (mock) was included. To
capture the immune-complexes 50 μl pre-blocked protein A agarose
beads were added for 1 h. Immune complexes were washed and
eluted. The protein-DNA cross-linking was reversed at 65 °C over-
night. The primers for PCR ampliﬁcation of the surfactant protein B
promoter are: Sftpb1 FP 5′-CACTTACCCTGCGTCAAGAG-3′, RP 5′-
GCCTGACTTTGTTCACGTC-3′ and Sftpb2 FP 5′-AAGGACTAGGAACCGA-
CATC-3′, RP 5′-ACTGCAGTAGGTGCGACTTG-3′. The PCR products were
sequenced using BigDye chemistry and an Avant 3100 Genetic
Analyzer (Applied Biosystems) to show product speciﬁcity.
2.11. Luciferase reporter gene assay
Cells were transfected with the Sftpb promoter luciferase reporter
plasmid [29] and the pRL-TK control Vector (renilla luciferase) alone
or together with the EGFP control plasmid, pHER4, or YFPERβ, as
described above. 48 h after transfection cells were starved for 3 h and
treated with DMEM (control), 17-β-estradiol (1000 pmol/l), or NRG
(33 nM) for 24 h. Luciferase assay was done using the Dual-Glo
Luciferase assay system. Brieﬂy, luciferase reagent was added to cells
in growth medium. After 10 minute incubation the ﬁreﬂy lumines-
cence was measured. Stop and Glo reagent was added to the cells and
renilla luciferase was measured after 10 minute incubation. For data
evaluation the ratio of luminescence from the experimental reporter
to the luminescence from the control reporter was calculated and
normalized to a control well.
2.12. Preparation of primary fetal mouse ErbB4 deleted type II epithelial
cell cultures
Primary type II cells were freshly isolated as previously described
[34,35]. Time dated pregnant transgenic ErbB4mice, rescued from their
lethal cardiac defects by expressing a human ErbB4 (HER4heart) cDNA
under the cardiac-speciﬁcα-myosin heavy chain promoter [36] (kindly
provided by Carmen Birchmeier in agreement with Martin Gassmann)
were used. All animals were housed in an animal facility at Hannover
Medical School, and the protocols were approved by the appropriate
governmental and institutional authorities at HannoverMedical School.
Time-dated pregnant HER4heart mice were sacriﬁced at E17.5 of
gestation by CO2 inhalation. The fetal lungs were removed, washed in
sterile Hank's buffered salt solution, and minced with a razorblade. The
minced lungs were incubated with Collagenase Type II for 2 h at 37 °C.
The reaction was stopped on ice for 30 min. The tissue was centrifuged,
the pelletwas resuspended in DMEM, and incubated for another 30 min
on ice. After a second centrifugation the pellet was resuspended in
DNase and trypsin and incubated for 12 min at 37 °C. The reaction was
stopped by DMEM containing 10% fetal calf serum (FCS). The cells were
ﬁltered, centrifuged, resuspended in DMEM containing 10% FCS, and
Table 1
Dose response of estrogen effect on cell viability.
17-β-Estradiol concentration 0 pmol/l 60 pmol/l 100 pmol/l 500 pmol/l 1000 pmol/l 1500 pmol/l
Cell viability 100±2% 85±2% 74±3% 82±2% 76±2% 78±2%
P value P=0.0002 Pb0.0001 Pb0.0001 Pb0.0001 Pb0.0001
Experimental repeats 7 3 6 3 7 3
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differential adherence of lung ﬁbroblasts. For type II cell isolation the
supernatants from the ﬁrst differential adherence were centrifuged
again. The cell pelletwas resuspended inDMEMcontaining10%FCS, and
plated in culture ﬂasks for 60 min at 37 °C for a second differential
adherence. Supernatants were removed and centrifuged. Cell pellets
were resuspended, plated inDMEMcontaining20%FCS, andgrownuntil
further use.
2.13. Data analysis
All treatment values were mean±SEM of experimental speciﬁc
controls unless otherwise stated. The effects of ERβ and ErbB4
overexpression on cell viability, surfactant protein expression, and
Sftpb promoter activity were expressed as percentages of EGFP-
treated controls. To evaluate the results for their statistical signiﬁ-
cance a two-way ANOVA or two tailed t-test with post hoc Bonferroni
correction for multiple comparisons was used when appropriate.
3. Results
3.1. Estrogen and NRG reduces cell number
We ﬁrst examined the effect of estrogen and NRG on the cell
number in a dose dependent manner. 17-β-estradiol (Table 1) as well
as NRG (Table 2) reduced the cell number at all tested concentrations.
We used 1000 pmol/l 17-β-estradiol or 33 nM NRG for all of the
following experiments since these doses are known to stimulate ERβ
and ErbB4 receptor phosphorylation, respectively [37].
3.2. Estrogen and NRG stimulate Sftpb mRNA and Sftpb protein expression
1000 pmol/l 17-β-estradiol and 33 nM NRG signiﬁcantly stim-
ulated Sftpb mRNA expression to 0.61±0.2 (n=6, P=0.02) and
0.56±0.2 (n=5, P=0.03), respectively (Fig. 1A), when compared
to untreated control cells. This stimulatory effect on Sftpb mRNA was
less intense on the protein level, implying the presence of post-
transcriptional modiﬁcation. Sftpb protein expressionwas signiﬁcant-
ly increased after 17-β-estradiol (114±5%, n=5, P=0.02) or NRG
(119±3%, n=5, P=0.004) treatment compared to untreated control
cells (100±4%, n=5) (Fig. 1B).
3.3. ERβ and ErbB4 co-immunoprecipitate each other
Interactions of ERβ and ErbB4 were studied using a co-
immunoprecipitation (co-IP) protocol. ERβ and ErbB4 co-precipitated
each other (Fig. 2), independently of treatment with 17-β-estradiol
or NRG. In the ERβ co-IP, 17-β-estradiol (116±10%, n=4, P=0.1)Table 2
Dose response of NRG effect on cell viability.
NRG concentration 0 nM 5 nM 10 nM
Cell viability 100±2% 79±3% 83±3%
P value Pb0.0001 Pb0.0001
Experimental repeats 7 3 3and NRG (106±15%, n=3, P=0.6) did not signiﬁcantly change the
baseline endogenous ErbB4 tyrosine phosphorylation, but signiﬁcant-
ly stimulated the phosphorylation of ERβ (135±5%, n=4, P=0.0002;
109±4%, n=3, P=0.03, respectively) above the endogenous phos-
phorylation of this receptors (100±0.3%, n=4; 100±0.3%, n=4
respectively) (Fig. 2A). In the ErbB4 co-IP, treatment with 17-β-
estradiol or NRG decreased ErbB4 (88±5%, n=4, P=0.05; 91±10%,
n=3, P=0.3 respectively) and the co-precipitated ERβ (86±6%,
n=4, P=0.05; 74±13%, n=3, P=0.05 respectively) phosphoryla-
tion compared to the endogenous phosphorylation of this receptors
(100±3%, n=4; 100±3%, n=4 respectively) (Fig. 2B). Immunopre-
cipitations with a control IgG antibody did not show any non-speciﬁc
antibody binding (Fig. S1).
3.4. Estrogen and NRG stimulate cellular co-localization of ERβ and
ErbB4
The intracellular receptor localization was studied using confocal
microscopy. In non-stimulated control cells, ERβ showed a diffuse
intracellular localization pattern, mainly in the nucleus and the
perinuclear region. ErbB4 is localized in the cell membrane and the
cytoplasm (Fig. 3A). A short 2-minute stimulation with 17-β-estradiol
or NRG led to nuclear localization of ERβ and perinuclear localization
of ErbB4 with some co-localization with estrogen stimulation only
(Fig. 3B, F). Estrogen or NRG treatment for 30 min (data not shown),
1 h (Fig. 3C, G), 4 h (data not shown), and 8 h (data not shown) led to
a cytoplasmatic localization of ErbB4 and no co-localization with the
nuclear localized ERβ. After 12 h of 17-β-estradiol or NRG treatment
co-localization of both receptors was found in the nucleus and the
perinuclear region (Fig. 3D, H). 24 h of NRG treatment further
increased the co-localization of both receptors mostly in the peri-
nuclear region (Fig. 3E, I), whereas estrogen induced some co-
localization at the cell membrane. Overall, NRG induced a more
efﬁcient and faster localization of ERβ in the cytoplasm with an
eventual pronounced localization in the perinuclear region and a
strong co-localization with ErbB4.
3.5. ERβ, but not ErbB4 overexpression increases cell number
To study the effect of ERβ overexpression on the cell number, MLE-
12 cells were transfected with ERβ (YFPERβ) resulting in a signiﬁcant
increase to 152±5% (n=16, Pb0.001) in comparison to EGFP-
transfected control cells (100±2%, n=12). 17-β-estradiol and NRG
treatment further enhanced this stimulatory effect to 155±8%
(n=10, Pb0.001) and 167±5% (n=7, Pb0.001), respectively,
while 17-β-estradiol and NRG treatment had no effect on EGFP-
transfected cells (84±6%, n=12, PN0.05; 94±5%, n=6, PN0.05,
respectively). Overexpression of ErbB4 using a human HER4 construct20 nM 33 nM 40 nM 100 nM
84±2% 86±2% 90±2% 91±4%
P=0.0002 Pb0.0001 P=0.015 P=0.063
3 4 3 3
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Fig. 1. Estrogen and NRG stimulate SftpbmRNA and Sftpb protein expression. SftpbmRNA expression was measured by real time PCR. 17-β-estradiol (light gray bar) and NRG (dark
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Fig. 2. ERβ and ErbB4 co-immunoprecipitated each other. Co-immunoprecipitation (Co-IP)
(left panel), after 17-β-estradiol (middle panel) and after NRG (right panel) stimulation. Blo
on the right next to the blots. Both receptors co-precipitated each other under all conditions.
(light gray bar) or NRG (dark gray bar) stimulated cells (n=3–4, *P≤0.05, **P≤0.005) waestradiol (1.4±0.3, n=5, Pb0.01) or NRG (1.2±0.1, n=4, Pb0.05)
treatment signiﬁcantly increased Sftpb mRNA expression when
compared to cells transfected with the EGFP control construct
(Fig. 5A).
Sftpb protein expression was on the other hand signiﬁcantly
increased after ERβ overexpression alone to 115±2% (n=3, Pb0.01).
17-β-estradiol treatment further increased Sftpb protein expression
to 120±5% (n=3, Pb0.001) while NRG treatment did not add further
stimulation (116±4%, n=3, Pb0.01). Results were compared toIP α-ErbB4B
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protocols were used to co-precipitate ERβ (A) and ErbB4 (B) under control conditions
ts were probed with anti-phosphotyrosine, anti-ErbB4, and anti-ERβ antibody as stated
Blots were analyzed by densitometric measurements. Phosphorylation of 17-β-estradiol
s compared to non-stimulated control cells (black bar).
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Fig. 3. Estrogen and NRG stimulate cellular co-localization of ERβ and ErbB4. Cellular co-localization of ERβ (red dye) and ErbB4 (green dye) was examined in non-stimulated control
cells (A) and after 2 min (B, F), 1 h (C, G), 12 h (D, H) or 24 h (E, I) 17-β-estradiol (estrogen) or NRG stimulation. DAPI staining was used to distinguish the nuclear region from the
cytoplasm (J). Nuclear receptor co-localization was most pronounced after 2 min 17-β-estradiol, and perinuclear co-localization after 12 h (D, H) and 24 h (E, I) 17-β-estradiol or
NRG treatment.
1722 K. Zscheppang et al. / Biochimica et Biophysica Acta 1813 (2011) 1717–1727EGFP-transfected control cells (100±1%, n=4). In EGFP-transfected
cells, 17-β-estradiol (102±1%, n=4, PN0.05) and NRG (106±2%,
n=4, PN0.05) alone had only a slight stimulatory effect on
Sftpb protein expression compared to EGFP-transfected control cells
(100±1%, n=4) (Fig. 5B).
3.7. ERβ and ErbB4 bind to the Sftpb promoter
In order to study if ERβ and ErbB4 are binding to the Sftpb
promoter region, MLE-12 cells were treated with 17-β-estradiol or
NRG and chromatin immunoprecipitation was performed. Primers
were designed for the Sftpb promoter region encompassing approx-300
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Fig. 4. ERβ, but not ErbB4 overexpression increased cell number. Cell number was
measured by MTT assay in MLE 12 cells transfected with ERβ or HER4 under control
conditions (black bar), and after treatment with 17-β-estradiol (light gray bar) or NRG
(dark gray bar). Results were compared to EGFP-transfected non treated control cells
(n=6–16, **P≤0.005).imately 200 bp intervals (Fig. 6A). Under control conditions (C), ErbB4
and ERβ antibody precipitated two Sftpb promoter regions (nt −379
to −199 and nt −175 to +39). 17-β-estradiol treatment also
recruited both receptors to these regions whereas NRG recruited only
ErbB4 to these two regions and ERβ only to the nt −379 to −199
region (Fig. 6B). The PCR products were sequenced using BigDye
chemistry and an Avant 3100 Genetic Analyzer (Applied Biosystems)
to conﬁrm product speciﬁcity (data not shown).
3.8. ERβ and ErbB4 overexpression induce Sftpb promoter activity
To determine if estrogen, ERβ, and/or ErbB4 overexpression would
stimulate the Sftpb promoter activity we transfected MLE-12 cells
with an Sftpb promoter luciferase reporter plasmid. 1000 pmol/l 17-β-
estradiol and 33 nM NRG signiﬁcantly stimulated luciferase activity
to 121±7% (n=7, P=0.002) and 120±4% (n=10, Pb0.0001),
respectively. The treated cells were compared to untreated control
cells (100±2%, n=11) (Fig. 7A). 17-β-estradiol treatment increased
luciferase activity to 134±18% (n=7, PN0.05) and NRG treatment
to 111±14% (n=10, PN0.05) in EGFP-transfected cells. We have
previously shown that co-transfection of the Sftpb promoter luciferase
reporter and full-length ErbB4 receptor signiﬁcantly increased
luciferase activity under control conditions and after NRG treat-
ment [38]. 17-β-estradiol treatment increased luciferase activity to
165±23% (n=5, PN0.05) in ErbB4 overexpressing cells (data not
shown). Co-transfection of the Sftpb promoter luciferase reporter and
ERβ increased luciferase activity to 157±45% (n=5, PN0.05) under
control conditions, to 229±81% (n=5, PN0.05) after 17-β-estradiol
treatment, and to 173±61% (n=5, PN0.05) after NRG treatment. A
combined overexpression of HER4 and ERβ further potentiated this
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Fig. 5. ERβ overexpression stimulated Sftpb mRNA and protein expression. Sftpb mRNA expression was measured by real time PCR (5A). SftpbmRNA was signiﬁcantly increased in
cells transfected with ERβ under control conditions (black bar) and after 17-β-estradiol (light gray bar) or NRG (dark gray bar) treatment. Results were compared to EGFP
transfected control cells (n=4–5, *P≤0.05, **P≤0.005). Sftpb protein expression was studied byWestern blotting and analyzed by densitometry (5B) (representative Western blot
was shown on the upper part of B). Again the ERβ overexpression signiﬁcantly stimulated Sftpb protein expression when compared to EGFP-transfected cells under control
conditions (black bar) and after 17-β-estradiol (light gray bar) or NRG (dark gray bar) treatment (n=3–4, *P≤0.05, **P≤0.005).
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Pb0.05) under control conditions, to 371±53% (n=4, Pb0.001) after
17-β-estradiol treatment, and to 278±78% (n=4, Pb0.05) after NRG
treatment. Transfected cells were compared to EGFP-transfected cells
under control conditions (100±4%, n=12) (Fig. 7B).A
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** **3.9. Estrogen induces ErbB4 nuclear translocation
To further analyze the importance of membrane cleavage and
nuclear entry of ErbB4 in the effects of estrogen induced co-regulation
of ERβ and ErbB4, we transfected MLE-12 cells with ErbB4 mutants
with an abrogated nuclear localization sequence (HER4muNLS) or
with an abolished γ-secretase processing domain (HER4V673IMu)
[25]. Full-length ErbB4 receptor (HER4) and both ErbB4 mutantsA
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Fig. 6. Binding of ErbB4 and ERβ to the Sftpb promoter. Primers were designed for the
Sftpb promoter region encompassing approximately 200 bp intervals (A). Cells were
mock treated (C) or treated with 17-β-estradiol (E) or NRG (N). ChIP assay was
performed and DNA bound to ErbB4 or ERβ was analyzed by semi-quantitative PCR
ampliﬁcation. The chromatin was immunoprecipitated using antibodies directed
against ErbB4 and ERβ. The input DNA was used as a positive control (Input) and a
no antibody negative control (Mock) was included. Under control conditions and after
17-β-estradiol or NRG treatment, ErbB4 and ERβ precipitated with two Sftpb promoter
regions (B).(HER4muNLS or HER4V673IMu) localized to the cell membrane and
the cytoplasm in the control condition. After 17-ß-estradiol treatment
the full-length ErbB4 receptor (HER4) and the ErbB4 mutant with an
abrogated nuclear localization sequence (HER4muNLS) localized toR
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Fig. 7. ERβ and ErbB4 overexpression induced Sftpb promoter activity. MLE-12 cells
were transfected with a Sftpb promoter luciferase reporter. Luciferase activity was
measured after 17-β-estradiol (light gray bar) or NRG (dark gray bar) treatment.
Results were compared to non-stimulated control cells (black bar), (n=4–11,
**P≤0.005) (A). Cells were co-transfected with EGFP, ERβ or a combination of HER4
and ERβ and luciferase activity was measured under control conditions (black bar) and
after 17-β-estradiol (light gray bar) or NRG (dark gray bar) treatment. Results were
compared to cells transfected with a control plasmid (EGFP) (n=4–12, *P≤0.05,
**P≤0.005) (B).
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Fig. 8. Estrogen induced ErbB4 nuclear translocation. MLE-12 cells were transfected with HER4 (full length ErbB4 receptor, upper panel), HER4MuNLS (abrogated nuclear
localization sequence, middle panel) or HER4V673IMu (abolished γ-secreatase processing domain, lower panel). Cellular localization of HER4 (green dye) was determined under
control conditions (left panel) and after 2 min of 17-β-estradiol stimulation (right panel). DAPI staining was used to distinguish the nuclear region from the cytoplasm (blue dye).
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processing domain (HER4V673IMu) remained in the cell membrane
and the cytoplasm. This underlines that γ-secretase processing of
ErbB4 seems to be required, while the nuclear localization sequence
seems not to be required for estrogen-induced nuclear localization
of ErbB4 (Fig. 8), suggesting that ER might function as a NRG-
independent nuclear shuttle for ErbB4.
3.10. ErbB4 deletion abolishes estrogen-induced increase in Sftpb mRNA
expression
In primary fetal E17.5 ErbB4-deleted type II cells freshly isolated
from HER4heart−/−mouse lungs, 17-β-estradiol (−0.04±0.2, n=3,
P=0.3) had no stimulatory effect on Sftpb mRNA expression, while
NRG signiﬁcantly decreased Sftpb mRNA (−0.4±0.3, n=3,
Pb0.0001). Expression of full-length human ErbB4 receptor (HER4)
restored the estrogen- (0.6±0.1, n=3, P=0.01) and the NRG-
induced (1.5±0.3, n=3, Pb0.0001) effects on Sftpb mRNA expres-
sion in ErbB4-depleted type II cells (Fig. 9).2
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Fig. 9. ErbB4 deletion abolished estrogen-induced increase in Sftpb mRNA expression.
HER4heart−/− cells were treated with 17-β-estradiol. Real time PCR measurements
showed that this treatment had an inhibitory effect on Sftpb mRNA expression (n=3;
**P≤0.005). Expression of HER4 increased Sftpb mRNA expression in 17-β-estradiol
treated cells (n=3, **P≤0.005).4. Discussion
Hormones and growth factors play important roles in the
developing lung [39]. Glucocorticoids are widely used in the clinical
setting to reduce the risk for RDS [40]. Progesterone, which is known
to prevent preterm birth [41] is being studied for its positive effect on
the surfactant system [42]. Sex differences in lung development are
well studied in the clinical and animal setting and are due to the
inhibitory inﬂuence of androgens [3] and the positive effect of
estrogen [8]. Even the effects of the antenatal glucocorticoid therapy
are more prominent in female newborns [43] suggesting a positive
interaction with estrogens. NRG [14,15], an important differentiation
factor, also exerts stimulatory effects on fetal lung maturation and
surfactant synthesis and is known to positively interact with ER in
other organ systems [26], but its signaling interactionwith estrogen in
the fetal lung has to be elucidated. Since type II cells highly express
ERβ and ErbB4 and both receptors are known to be very interactive
with other signaling pathways or proteins, we hypothesized that
estrogen stimulates Sftpb expression and that its stimulatory effect is
signaled through an interaction of ERβ and ErbB4 signaling pathways.
NRG-induced ErbB receptor signaling is known to be critical for
normal female sex development [20,44] and ErbB4 co-regulates ERα
in breast tumor cells [26]. The nuclear ERα/4ICD complex is
selectively recruited to estrogen-inducible gene promoters. Consis-
tent with 4ICD-selective promoter binding, suppression of ErbB4
expression shows that 4ICD co-activates ERα transcription. Notewor-
thy, ErbB4 itself is an estrogen-inducible gene and the ErbB4 promoter
harbors a consensus estrogen response element (ERE) half-site with
overlapping activator protein-1 elements that bind ERα and 4ICD in
response to estrogen. ERs are highly expressed in the fetal lung. In
fetal mouse lungs, ERα expression is highest earlier in gestation at
E15, while ERβ expression peaks at E17 [12] when fetal surfactant
synthesis is initiated. This underlines the importance of ER function in
fetal lung development, while the exact intracellular signaling and
interaction with other known important promoters of fetal lung
development still need to be elucidated. ERα was only weakly
expressed in mouse lung epithelial cells (MLE-12 cells) and had no
effect on Sftpb promoter activation (data not shown). Therefore we
here focused on the interaction of estrogen-induced ERβ signaling
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line. We are well aware that it might be difﬁcult to draw direct
conclusions from an epithelial cell line, established from amouse lung
tumor and further elucidation in primary fetal type II cells is required.
We used this cell line here, since transfection efﬁciency is less potent
in primary freshly isolated type II cells and on the other hand these
cells express characteristics of type II cells, including the expression of
Sftpb [27].
First, we studied the effects of estrogen and NRG on Sftpb
expression, the most critical surfactant protein in reducing surface
tension in the lung, supporting the adequate neonatal transition, and
their effects on cell number. Estrogen as well as NRG signiﬁcantly
stimulated the expression of Sftpb. The overall effects on Sftpb gene
expression were more pronounced than on Sftpb protein, suggesting
the presence of either a latency of protein production or posttrans-
lational modiﬁcations. To increase the estrogen-induced effect on
Sftpb expression we overexpressed ERβ, because the expression
intensity and the amount of ER might have an inﬂuence on multiple
cell functions.
Despite the fact that estrogen is known to be involved in cell
proliferation, it is also found to be present in more differentiated cells
with low proliferative activity [45,46]. It is known for multiple growth
factors that they are able to switch from a proliferative to a more
differentiation promoting activity. Both, estrogen as well as NRG
decreased the cell number in our type II epithelial cells. The growth
factor NRG is required for the initiation of fetal surfactant synthesis
[15] and its signaling receptor ErbB4 is known to be preferably
involved in differentiation processes than in cell proliferation [17–20].
Since different concentrations of estrogen and NRG did not reveal
signiﬁcant differences on the cell number and 1000 pmol/l 17-β-
estradiol and 33 nM NRG had a stimulatory effect on Sftpb, these
concentrations were used for all experiments. The physiological 17-β-
estradiol concentration in amniotic ﬂuid increases with gestational
age [47]. The concentration we used correlates well with the
concentration found in fetal plasma of guinea pigs [48], in fetal ﬂuids
and cord blood of pigs [49], and in fetal mouse lungs [50] at an early
time point in gestation. This estrogen dose is also known for its
stimulatory effect on ER and ErbB4 interactions in breast cancer cells
[37]. The NRG dose we used is known to stimulate ErbB receptor
phosphorylation in these cells [15].
Secondly, we used co-immunoprecipitation experiments to study
the intracellular and nuclear interactions of ERβ and ErbB4 in these
type II cells. Interactions found with this technique were endogenous
and independent of further estrogen and NRG stimulation. Estrogen
signiﬁcantly stimulated tyrosine phosphorylation of ERβ in type II
cells, but had an inhibitory effect on ErbB4 phosphorylation. Despite
this observation, interactions of both receptors were critical for the
effect of estrogen on Sftpb as seen with the following experiments.
Intracellular localization studies conﬁrmed cellular interactions. Both
estrogen and NRG stimulated nuclear co-localization of both receptors
in a time-dependent manner, underlining the importance of their
interactions. ErbB4 is unique in the ErbB receptor family, since the
intracellular domain of ErbB4 (4ICD) is able to translocate to the
nucleus through a proteolytic cleavage mechanism [22]. Nuclear
localization sequences (NLSs) of EGFR family members are required
for the nuclear function of these receptors [51]. Estrogen receptors, on
the other hand, are nuclear receptors and the classic estrogen
signaling is initiated by binding of estrogen to the ER [52]. The non-
classical signaling of estrogen through a membrane-associated ER,
results in the formation of complexes with receptor tyrosine kinases,
G-protein coupled receptors, or secondarymessengers like cyclic AMP
[53,54]. In breast cancer cells, estrogen promotes direct coupling of
the transmembrane ErbB4 and ERα, leading to subsequent complex
formation of ERα and the proteolytic processed ErbB4 intracellular
domain (4ICD). This complex translocates to the nucleus and binds to
gene promoters containing EREs [26]. Our present experiments showfor the ﬁrst time that estrogen effects on Sftpb require ErbB4 signaling
interactions in lung epithelial type II cells. Estrogen-induced co-
localization of both receptors occurred in the nucleus and in the
perinuclear region of type II cells. NRG induced co-localization in a
more timely fashion in the membrane ﬁrst, followed by a more
intense co-localization in the perinuclear region. The membrane co-
localization is in alignment with the membrane coupling of ErbB4 and
ERα described inmammary cells [26]. It might be speculated that such
a response is also present in lung epithelial cells and that the estrogen
receptor serves as a nuclear shuttle for ErbB4.
Thirdly to further study the effects of estrogen- and NRG-induced
ERβ signaling on the cell number and surfactant protein expression
we overexpressed this receptor in the MLE-12 cells, resulting in
stimulation of both, cell number and Sftpb expression. The stimulatory
effect on the cell number, which was further increased by estrogen
and NRG treatment, is in keeping with the known stimulatory effects
of estrogen in ER overexpressing tumor cells [45,46]. This also
conﬁrms that NRG-induced ErbB4 activation is required for the
growth promoting action of estrogen [26]. It is somewhat surprising
that estrogen treatment alone decreased the cell number in these
cells. In many developing organ systems, including the fetal lung, cell
differentiation is accompanied by reduced cell proliferation [55,56]. It
is known that estrogen has a stimulatory effect on the cell number in
ER overexpressing tumor cells, but in more differentiated cells
estrogen leads to a lower proliferative activity [45,46]. The expression
intensity, the amount, and the cellular localization of ER might also be
involved in the diversity of effects on multiple cell functions including
cell proliferation and cell differentiation. For example the estrogen-
induced proliferation of neural stem/progenitor cells is mediated via
nuclear ER while estrogen-induced differentiation of these cells is
mediated by membrane-associated ER [57].
The effects of ERβ overexpression on cell proliferation were
distinct from the effects of ErbB4 overexpression, suggesting that
estrogen effects on the cell number might be independent of ErbB4
signaling. This was not the case for their effect on the Sftpb expression,
requiring an interaction of both receptors. This is in agreement with
the known fact that ErbB4 is a member of the ErbB receptor family
that is mostly involved in differentiation of organ function [58]. These
differences in effect might also be involved in the known “tension”
between maturation and proliferation processes happening in many
areas of organ development [58,59] where cell differentiation is
accompanied by reduced cell proliferation [55,56].
Finally, co-localization of ERß and ErbB4 and the stimulatory effect
of estrogen and NRG on Sftpb expression, raise the possibility that
both receptor proteins form a functionally important complex to
stimulate Sftpb expression by binding to the promoter region of this
gene. There are highly conserved regions located 100 and 300 bp
downstream of the transcription start region in the Sftpb promoter,
which contain DNase hypersensitivity and footprinting sites, suggest-
ing the presence of transcription factor binding sites [60]. Our results
presented here suggest that both proteins bind to the promoter
region, but ErbB4 is needed for estrogen-induced effects on Sftpb
promoter activity. Since the estrogen-induced nuclear entry did not
require a competent nuclear localization sequence in the ErbB4
receptor, we speculate that ERβ functions as a nuclear chaperone for
ErbB4 through a different nuclear entrymechanism.We conclude that
estrogen-induced nuclear translocation of the proteolytic processed
4ICD is required for the stimulatory effect of estrogen on Sftpb
expression. ErbB4 might function as a transcriptional co-factor in the
regulation of estrogen-induced Sftpb gene upregulation in type II
epithelial cells. There is growing evidence from clinical and basic
research that NRG receptor ErbB4 regulates estrogen-related molec-
ular biology of disease processes, mostly through interaction of ErbB4
and ERα [26,61]. This might hold true for the development of RDS in
the setting of preterm labor. Since NRG might be a potential protector
in preterm infants [62–64], further elucidation of this interaction in
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were done in a cell line.5. Conclusion
In summary, our data show that ErbB4 regulates estrogen effects
on Sftpb expression in this mouse cell line of epithelial type II cell
origin. We speculate that the interactions of ERß and ErbB4 signaling
pathways might play an important role in lung development by
positively inﬂuencing the fetal surfactant system. Estrogen is well-
known for its positive postnatal effects, improving pulmonary
function and decreasing ventilatory support requirement in preterm
primates [65], but evidence is missing that it leads to a signiﬁcant
reduction in the incidence or severity of BPD [66]. Activating ErbB4
signaling might be a possibility to positively enhance morphologic
lung development in addition to the known positive effects of
estrogen treatment on the surfactant system. Further studies in the
developing lung are warranted to conﬁrm the role of ErbB4 as a
transcriptional regulator of estrogen signaling.
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